The U.S. government is conducting its most substantial review of cannabis policy in half a century, prompted by expanding state legalization and shifting public opinion. Cannabis remains a Schedule I substance under federal law, though the Department of Health and Human Services has recommended moving it to Schedule III, recognizing its medical use and lower risk potential.
A shift to Schedule III would not legalize cannabis nationwide but could ease research barriers, adjust tax rules, and better align federal policy with state systems. Key federal restrictions—such as interstate trade and banking limits—would persist without new congressional action.
This reassessment underscores how far public and political perspectives have moved since the Controlled Substances Act was enacted in 1970. With most Americans now supporting medical cannabis, the federal decision—still pending—may reshape research, business, and healthcare policy for years to come.
